Abbvie Inc.

Abbvie B.v.

Abbott Laboratories Corporation

Abbvie Bahamas Limited

Abb Vie Deutschland Gmbh & Co. Kg

Abbvie Biotherapeutics Inc.

Abbivie Inc.

Adrian Hobson

Wouter I Iwema Bakker

Hein K A C Coolen

Maria J P Van Dongen

Axel Stoit

Lu Wang

Helmut Mack

Anil Vasudevan

Nicole Teusch

Eric C Breinlinger

Dawn M George

Nicolas J-l D Leflemme

Pieter Smid

Leonardus A J M Sliedregt

Jacobus A J Den Hartog

Biqin C Li

Kevin Patrick Cusack

Dominique Bonafoux

Christopher C Marvin

Steven Lewis Swann, Jr

Hein Kac Coolen

Thomas Dale Penning

Wilfried Hornberger

Stevan Wakefield Djuric

Sean Colm Turner

Julie M Miyashiro

Alan Frank Gasiecki

Keith W Woods

Jyoti R Patel

Michael M Friedman

Daryl Richard Sauer

Qi Shuai

Martine Barth

Irini Akritopoulou-Zanze

Ryan G Keddy

Kathy A Sarris

Maria A Argiriadi

Douglas M Kalvin

Brian D Wakefield

Melissa J Michmerhuizen

Graham K Ansell

Eric Ronken

Martin E Hayes

Vijaya J Gracias

Michael McPherson

Michael F Jarvis

Shannon R Fix-Stenzel

Andrew J Long

Axel Hernandez, Jr

Wendy Waegell

Pintipa Grongsaard

Peter J Kovar

Eric F Johnson

Christian Goess

Jurjen Frankena

Elizabeth Van Der Kam

Harmen Mons

Dominique Potin

Maria Jp Van Dongen

Shuhui Chen

John T Randolph

Michael E Kort

Kevin R Woller

Thomas D Gordon

Wentao Wu

Richard W Dixon

Bernhard K Mueller

Neil Wishart

Jianfei Wang

Grier A Wallace

Didier Thomas

Xiaoyun Wu

Fabrice Guillier

James W Purcell

Margaretha Bakker

Jerome Amaudrut

Diana L Schmidt

Jérôme Amaudrut

Robert H Stoffel

Jeremy Edmunds

N St John Moore

Bernhard K Muller

Linlin Dai

Nigel S Moore

Margaretha H M Bakker

Ling C Santora

Jason Z Oh

Olivia Poupardin

Laurent Mounier

Steve Swann, Jr

Van Der Elizabeth Kam

Hein KAC Coolen

Axel Hernandez Jr

Nicolas J-Ld Leflemme

Leonardus Ajm Sliedregt

Jacobus Aj Den Hartog

Diana Schmidt

Michael J McPherson

The present disclosure provides anti-CD19 antibody drug conjugates (ADCs), including compositions and methods of using such ADCs.

Anti-CD19 antibody drug conjugates

The present invention relates spiro-cyclic amine derivatives of the formula (I) wherein R1; R2; R3; Q; &#x2014;W-T-; R5; Z; and A have the definitions provided in the claims; or a pharmaceutically acceptable salt, a solvate or hydrate thereof or one or more N-oxides thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of diseases and conditions in which (a) S1P receptor(s) is(are) involved. 

Spiro-cyclic amine derivatives as S1P modulators

This invention relates to new fused heterocyclic derivatives having affinity to S1P receptors, a pharmaceutical composition containing said compounds, as well as the use of said compounds for the preparation of a medicament for treating, alleviating or preventing diseases and conditions in which any S1P receptor is involved or in which modulation of the endogenous S1P signaling system via any S1P receptor is involved.

Fused heterocyclic derivatives as S1P modulators

The present invention relates spiro-cyclic amine derivatives of the formula (I) wherein R1; R2; R3; Q; &#x2014;W-T-; R5; Z; and A have the definitions provided in the claims; or a pharmaceutically acceptable salt, a solvate or hydrate thereof or one or more N-oxides thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of diseases and conditions in which (a) S1P receptor (s) is (are) involved. 

Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same.

Glucocorticoid receptor agonist and immunoconjugates thereof

Provided herein are glucocorticoid receptor agonist immunoconjugates, glucocorticoid receptor agonists, and methods of using the same, e.g., to treat autoimmune or inflammatory diseases.

The present invention relates to spiro-cyclic amine derivatives of the formula (I)  The compounds of the invention have affinity to SP receptors and may be used in the treatment, alleviation or prevention of diseases and conditions in which (a) SP receptor(s) is (are) involved.

The invention provides compounds of Formula (I) pharmaceutically acceptable salts, thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological conditions.

Nuclear receptor modulators

The present invention relates spiro-cyclic amine derivatives of the formula (1) wherein R1; R2; R3; Q; &#x2014;W-T-; R5; Z; and A have the definitions provided in the claims; or a pharmaceutically acceptable salt, a solvate or hydrate thereof or one or more N-oxides thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of diseases and conditions in which (a) S1P receptor (s) is (are) involved. 

The present invention relates to a fused heterocyclic derivative of the formula (I) The variables R1-R4, z, A, Q, X and Y are as defined in the claims. The following heterocycles are exemplified sub-structures of formula (I): The compounds of formula (I) are modulators of the S1P receptor (Sphingosine-1-phosphate receptor), More specifically, they are agonists of S1P5. The compounds have therapeutic use in treatment of cognitive disorders, age-relate cognitive decline and dementia.

The present disclosure relates to (thio)morpholine derivatives of the formula (I) or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the invention have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

(Thio)morpholine derivatives as S1P modulators

The present invention relates to compounds of formula (I) or pharmaceutical acceptable salts, wherein A, R, R, Rand m, are defined in the description. The present invention relates also to methods of making said compounds, and compositions containing said compounds which are useful for inhibiting kinases such as Glycogen Synthase kinase 3 (GSK-3), Rho kinase (ROCK), Janus Kinases (JAK), Cdc7, AKT, PAK4, PLK, CK2, KDR, MK2, JNK1, aurora, pim 1 and nek 2.

5-substituted indazoles as kinase inhibitors

The invention provides a compound of Formula (I) pharmaceutically acceptable salts, pro-drugs, biologically active metabolites, stereoisomers and isomers thereof wherein the variable are defined herein. The compounds of the invention are useful for treating immunological and oncological conditions.

Substituted 2,10-dihydro-9-oxa-1,2,4A-triazaphenanthren-3-ones and uses thereof

The present invention relates to a fused heterocyclic derivative of the formula (I) The variables R1-R4, z, A, Q, X and Y are as defined in the claims. The following heterocycles are exemplified sub-structures of formula (I): The compounds of formula (I) are modulators of the S1P receptor (Sphingosine-1-phosphate receptor), More specifically, they are agonists of S1P5. The compounds have therapeutic use in treatment of cognitive disorders, age-relate cognitive decline and dementia. 

The present disclosure relates to (thio)morpholine derivatives of the formula (I) or a pharmaceutically acceptable salt, a solvate or hydrate thereof; with the proviso that the derivative of formula (I) is not 2-(4-ethylphenyl)-4-morpholinoethanol or 4-[4-(2-hydroxyethyl)-2-morpholinyl]benzeneacetonitrile or a pharmaceutically acceptable salt, a solvate or hydrate thereof. The compounds of the disclosure have affinity to S1P receptors and may be used in the treatment, alleviation or prevention of S1P receptor mediated diseases and conditions.

Growing community of inventors

Shrewsbury, MA, United States of America

Adrian Hobson